Pre-transplant testing
Supporting patients on the transplant journey
Featuring both routine and esoteric assays, our robust portfolio of pre-transplant testing provides critical information to help nephrologists and transplant physicians make the best decisions for patients undergoing kidney transplantation.
Backed by data and developed around patient needs, our kidney transplant testing covers a broad range of medical specialties, including renal, infectious diseases, hematology, toxicology, genetics, and beyond.
PRETRANSPLANT TEST MENU
Hematology
From routine blood tests to innovative methods to screen for monoclonal proteins, our hematologic evaluations provide informative, pre-transplant insights.
Key testing
- QMPSS | Monoclonal Protein Study, Quantitative, Serum
- FLCS | Immunoglobulin Free Light Chains, Serum
Additional tests
- 25HDN | 25-Hydroxyvitamin D2 and D3, Serum
- ABOMR | ABO/Rh, Blood
- APTSC | Activated Partial Thromboplastin Time (APTT), Plasma
- B12 | Vitamin B12 Assay, Serum
- BTR | Isoagglutinin Titer, Anti-B, Serum
- CBC | Complete Blood Cell Count (CBC) with Differential, Blood
- DIMER | D-Dimer, Plasma
- EPO | Erythropoietin, Serum
- FB12 | Vitamin B12 and Folate, Serum
- FERR1 | Ferritin, Serum
- HBA1C | Hemoglobin A1c, Blood
- PTTP | Prothrombin Time, Plasma
- RETB | Reticulocyte Profile, Blood
- SFEC | Iron and Total Iron-Binding Capacity, Serum
Highlights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Infectious diseases
Identifying the presence of infectious pathogens in kidney transplant recipients is integral to understanding how best to care for patients. Our full slate of infectious disease testing evaluates for fungal and viral infections that pose a risk for pre-transplant patients.
Key testing
- COXIS | Coccidioides Antibody Screen with Reflex, Serum
- HCVQN | Hepatitis C Virus (HCV) RNA Detection and Quantification by Real-Time Reverse Transcription-PCR, Serum
- HIBAG | Histoplasma and Blastomyces Antigen, Enzyme Immunoassay, Serum
Additional tests
- AHDV | Hepatitis D Virus Total Antibodies, Serum
- BILHA | Schistosoma species Antibody, IgG, Serum
- CMVG | Cytomegalovirus (CMV) Antibodies, IgG, Serum
- CORAB | Hepatitis B Virus Core Total Antibodies, with Reflex to Hepatitis B Virus Core IgM Antibody, Serum
- CRUZI | Trypanosoma cruzi (Chagas) Antibody Panel, Serum
- EAEBV | Epstein-Barr Virus Early Antigen, IgG, Serum
- EBVAB | Epstein-Barr Virus Antibody Profile, Serum
- HAVTA | Hepatitis A Virus Total Antibodies, Serum
- HBAB | Hepatitis B Virus Surface Antibody, Qualitative/Quantitative, Serum
- HBAG | Hepatitis B Virus Surface Antigen, Serum
- HBBSN | Hepatitis B Virus Surface Antibody Screen, Qualitative/Quantitative, Serum
- HBC | Hepatitis B Virus Core Total Antibodies, Serum
- HBCSN | Hepatitis B Virus Core Total Antibodies Screen, Serum
- HBGSN | Hepatitis B Virus Surface Antigen Screen, Serum
- HBVQN | Hepatitis B Virus (HBV) DNA Detection and Quantification by Real-Time PCR, Serum
- HCSRN | Hepatitis C Virus (HCV) Antibody Screen with Reflex to HCV RNA, PCR, Asymptomatic, Serum
- HCVDX | Hepatitis C Virus (HCV) Antibody with Reflex to HCV RNA, PCR, Symptomatic, Serum
- HIVSS | HIV-1 and HIV-2 Antigen and Antibody Routine Screen, Serum
- HSVG | Herpes Simplex Virus (HSV) Type 1- and Type 2-Specific Antibodies, IgG, Serum
- HTLVI | Human T-Cell Lymphotropic Virus Types I and II Antibody Screen with Confirmation, Serum
- HVCOP | HIV-1 and HIV-2 Antigen and Antibody Routine Screen, Plasma
- MMRV | Measles, Mumps, Rubella, and Varicella (MMRV) Immune Status Profile, Serum
- MRSAP | Methicillin Resistant Staphylococcus aureus, PCR, Nasal
- QFT4 | QuantiFERON-TB Gold Plus, Blood
- STRNG | Strongyloides Antibody, IgG, Serum
- SYPH1 | Syphilis IgG with Reflex, Enzyme Immunoassay, Serum
- TOXGP | Toxoplasma gondii Antibody, IgG, Serum
- TPPA | Syphilis Antibody, Treponema pallidum Particle Agglutination, Serum
- TXMGP | Toxoplasma gondii Antibody, IgM and IgG, Serum
- VZPG | Varicella-Zoster Antibody, IgG, Serum
Highlights
Elitza Theel, Ph.D., explains how Mayo Clinic Laboratories' unique Histoplasma/Blastomyces test provides cost-effective evaluation for fungal infections that cause pulmonary illness. The assay reliably detects both Histoplasma and Blastomyces pathogens in a single test.
In this month's "Hot Topic," Elitza Theel, Ph.D., shares the recommended approach to serologic testing for assessment or infection with coccidioides.
Kidney function
A well-established, early and accurate biomarker of chronic kidney disease is serum cystatin C. Cystatin C testing is especially helpful in pre-transplant patients for whom creatinine testing is inadequate or for those whom glomerular filtration rate (GFR) measurement testing is impractical.
Key testing
Additional tests
- ALB | Albumin, Serum
- ALBR | Albumin, Random, Urine
- CRCL | Creatinine Clearance, Serum and 24-Hour Urine
- CRTS1 | Creatinine with Estimated Glomerular Filtration Rate (eGFR), Serum
- CTU | Creatinine, 24 Hour, Urine
- PTU | Protein, Total, 24 Hour, Urine
- RCTUR | Creatinine, Random, Urine
- RPTU1 | Protein/Creatinine Ratio, Random, Urine
Liver function
Assessing the liver function in patients prior to a kidney transplant can help detect potential complications early and enable timely interventions. We offer several assays for measuring liver function prior to transplant to help identify potential issues before problems arise.
Testing
- ALKP | Alkaline Phosphatase, Total and Isoenzymes, Serum
- ALP | Alkaline Phosphatase, Serum
- ALT | Alanine Aminotransferase (ALT) (GPT), Serum
- AST | Aspartate Aminotransferase (AST) (GOT), Serum
- BILI3 | Bilirubin, Serum
- BILID | Bilirubin Direct, Serum
- BILIT | Bilirubin, Total, Serum
- LIVPR | Liver Profile, Serum
Metabolic
Our comprehensive menu of metabolic evaluations provides essential data on donor compatibility, sensitization, metabolism, and comorbidities to assist transplant physicians and nephrologists in identifying potential metabolic issues prior to transplantation.
Testing
- 25HDN | 25-Hydroxyvitamin D2 and D3, Serum
- BMAMA | Basic Metabolic Panel, Serum
- BUN | Blood Urea Nitrogen (BUN), Serum
- CA | Calcium, Total, Serum
- CAI | Calcium, Ionized, Serum
- CHOL | Cholesterol, Total, Serum
- CL | Chloride, Serum
- CPR | C-Peptide, Serum
- GLURA | Glucose, Random, Serum
- HBA1C | Hemoglobin A1c, Blood
- HCO3 | Bicarbonate, Serum
- HDCH | Cholesterol, High-Density Lipoprotein (HDL), Serum
- KS | Potassium, Serum
- LDLD | Low-Density Lipoprotein (LDL) Cholesterol, Beta-Quantification, Serum
- LPSC1 | Lipid Panel, Serum
- MGS | Magnesium, Serum
- NAS | Sodium, Serum
- PHOS | Phosphorus (Inorganic), Serum
- PTH2 | Parathyroid Hormone, Serum
- STSH | Thyroid-Stimulating Hormone-Sensitive (s-TSH), Serum
- TRIG1 | Triglycerides, Serum
Pharmacogenomic
Pharmacogenomic (PGx) testing can identify genetic variants that might impact how kidney transplant patients metabolize medications. Establishing a patient’s PGX profile prior to transplant enables optimized, individualized medication selection that decreases the risk of complications and the need for additional treatments.
Key testing
Highlights
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.
Renal pathology
Our renal pathology testing can assist transplant physicians in evaluating certain causes of kidney disease in kidney transplant recipients.
Key testing
- MSMN | Membranous Nephropathy Target Antigen Identification, Mass Spectrometry, Tissue
- NELL1 | Neural Epidermal Growth Factor-Like 1 Protein Immunostain, Technical Component Only
- RPCWT | Renal Pathology Consultation, Wet Tissue
Additional tests
- ALPRT | Alport (Collagen IV Alpha 5 and Alpha 2) Immunofluorescent Stain, Renal Biopsy
- AMPIP | Amyloid Protein Identification, Paraffin, Mass Spectrometry
- DNJB9 | DNAJB9 Immunostain, Technical Component Only
- EXT2 | Exostosin 2 (EXT2) Immunostain, Technical Component Only
- IGG4I | IgG4 Immunostain, Technical Component Only
- MSCG | Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry
- MSFGN | Fibrillary Glomerulonephritis Confirmation, Mass Spectrometry, Paraffin Tissue
- MSFNG | Fibronectin Glomerulopathy Confirmation, Mass Spectrometry
- PLAIF | Phospholipase A2 Receptor (PLA2R), Renal Biopsy
- SEMA3 | Semaphorin 3B (SEMA3B) Immunostain, Technical Component Only
- SUBIF | Immunoglobulin G (IgG) Subtypes Immunofluorescence, Tissue
- THSIF | Thrombospondin Type 1 Domain Containing 7A (THSD7A), Immunofluorescence
Highlights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.
Rheumatology
Identifying whether kidney transplant patients are affected by rheumatic diseases is important, as these conditions can impact transplant success. Among our rheumatologic offerings for pre-transplant patients are antibody evaluations and complement testing.
Key testing
Additional tests
- ADNA1 | Double-Stranded DNA (dsDNA) Antibodies, IgG, Serum
- ANA2 | Antinuclear Antibodies (ANA), Serum
- ANCA | Cytoplasmic Neutrophil Antibodies, Serum
- C3 | Complement C3, Serum
- C4 | Complement C4, Serum
- CCP | Cyclic Citrullinated Peptide Antibodies, IgG, Serum
- CRY_S | Cryoglobulin, Serum
- JO1 | Jo 1 Antibodies, IgG, Serum
- MPO | Myeloperoxidase Antibodies, IgG, Serum
- PR3 | Proteinase 3 Antibodies, IgG, Serum
- RFPN | Rheumatoid Factor Panel, Serum
- RHUT | Rheumatoid Factor, Serum
- SM | Smith (Sm) Antibodies, IgG, Serum
- SSB | SS-B/La Antibodies, IgG, Serum
Toxicology
We offer a full menu of assays, including comprehensive profiles and ethanol testing, to help kidney transplant physicians better understand a patient’s substance use practices and possible risk from those practices. Screening for substance use disorders before transplant helps clarify whether a transplant recipient will be able to manage and minimize risks following transplantation.
Key testing
- ADMPU | Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
- CSMEU | Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
- ETGC | Ethyl Glucuronide Confirmation, Random, Urine
- ETGR | Ethyl Glucuronide Screen with Reflex, Random, Urine
- NICOS | Nicotine and Metabolites, Serum
- PETH | Phosphatidylethanol Confirmation, Blood
Highlights
Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in smoking cessation programs and other settings.
Mayo Clinic Laboratories has developed a new direct ethanol biomarker test for alcohol consumption that has a much longer detection window than existing urine tests for alcohol use.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
Bringing together advanced testing technology, unparalleled expertise, and a patient-focused approach, Mayo Clinic Laboratories’ new high-resolution urine drug testing profile, ADMPU, evaluates for 22 drug classes including alcohol, marijuana, and nicotine, enabling clarity on substance use and precision insights that propel treatment.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.